Piper Sandler analyst Joseph Catanzaro initiated coverage with a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $7.10.
Catanzaro covers the Healthcare sector, focusing on stocks such as Exelixis, Halozyme, and Keros Therapeutics. According to TipRanks, Catanzaro has an average return of 5.1% and a 42.70% success rate on recommended stocks.
Currently, the analyst consensus on Repare Therapeutics is a Strong Buy with an average price target of $19.80, a 178.87% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $15.10 and a one-year low of $3.08. Currently, Repare Therapeutics has an average volume of 384.2K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RPTX in relation to earlier this year. Last month, Koehler Maria, the EVP, Chief Medical Officer of RPTX bought 43,746.00 shares for a total of $98,596.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repare Therapeutics (RPTX) Company Description:
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Read More on RPTX:
